ADMA Biologics Inc vs ARK Next Generation Internet ETF — how do they compare? ADMA Biologics Inc trades at $9.94 (market cap $2.22B), while ARK Next Generation Internet ETF trades at $149.98. The key difference: ARK Next Generation Internet ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ARKW | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $182.20 |
52-Week Low | $7.60 | $114.45 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
ARKW trades at $150.88, up 0.87% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The ETF focuses on next-generation internet companies, though key financial ratios are not disclosed in the provided data. Recent news highlights long-term growth potential in AI and cloud infrastructure, balanced by near-term capital spending headwinds.
The outlook is mixed, with strong technical momentum but fundamental metrics unavailable for valuation. Risks include market skepticism on AI investments and sector volatility. Analyst sentiment is cautious, citing near-term challenges despite long-term positioning in transformative technologies.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →